Dynavax Technologies (NASDAQ:DVAX) Upgraded by StockNews.com to Buy Rating

Dynavax Technologies (NASDAQ:DVAX) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Separately, HC Wainwright boosted their target price on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday.

Dynavax Technologies Price Performance

Shares of DVAX stock remained flat at $12.48 during mid-day trading on Tuesday. The stock had a trading volume of 1,464,350 shares, compared to its average volume of 2,092,156. The stock has a market capitalization of $1.64 billion, a P/E ratio of 96.01 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The business has a fifty day moving average price of $12.76 and a two-hundred day moving average price of $11.65. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $14.41.

Hedge Funds Weigh In On Dynavax Technologies

Hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. bought a new position in shares of Dynavax Technologies in the 3rd quarter worth about $8,291,000. Entropy Technologies LP bought a new stake in Dynavax Technologies in the third quarter worth approximately $462,000. Bank of Montreal Can boosted its holdings in shares of Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after buying an additional 82,449 shares in the last quarter. Millennium Management LLC acquired a new stake in shares of Dynavax Technologies during the 2nd quarter worth approximately $17,615,000. Finally, Nordea Investment Management AB increased its stake in shares of Dynavax Technologies by 42.7% in the 4th quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares in the last quarter. Institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.